Peer-reviewedCC BYBiomedicines
Personalizing Inhaled Therapy in COPD and Asthma: Integrating Drug, Device, and Patient Factors
- 1Department of Internal Medicine, , New Taipei City 220, Taiwan;
Related
- Is It Safe to Reduce Inhaled Corticosteroid Dose in Severe Asthma Patients Receiving Biologic Therapy?
- From respiratory cultures to empirical treatment: Integrating local resistance data, colonization risk, and patient-level factors in hospital-acquired pneumonia
- Factors Associated With Patient‐Reported Outcomes More Than 5 Years After Dental Implant Therapy: A Cross‐Sectional Study
- Chronic Obstructive Pulmonary Disease in Heart Failure with Reduced Ejection Fraction: Prevalence, Prognostic, and Association of Triple Inhaled Therapy
- From Quiet Asthma to Clinical Remission: Can Optimized Maximal Inhaled Therapy Achieve Biologic-Free Remission in Difficult-to-Treat and Severe Asthma?
BibTeX
@article{yung2026personalizing,
title = {{Personalizing Inhaled Therapy in COPD and Asthma: Integrating Drug, Device, and Patient Factors}},
author = {Kenneth Yung and Shih-Lung Cheng},
journal = {Biomedicines},
year = {2026},
month = sep,
url = {https://europepmc.org/article/PMC/PMC13701278},
note = {CC BY},
}
RIS
TY - JOUR
TI - Personalizing Inhaled Therapy in COPD and Asthma: Integrating Drug, Device, and Patient Factors
AU - Kenneth Yung
AU - Shih-Lung Cheng
PY - 2026
DA - 2026/09/26
JO - Biomedicines
UR - https://europepmc.org/article/PMC/PMC13701278
SN - 2227-9059
ER -